Unlock instant, AI-driven research and patent intelligence for your innovation.

Molecular chaperone function regulator

A technology of molecular chaperones and regulators, which can be used in organic active ingredients, endocrine system diseases, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2007-08-01
MITSUBISHI TANABE PHARMA CORP
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] On the other hand, there are no reports directly showing that compounds with a quinazoline backbone structure can modulate chaperone function, and there are no findings suggesting such a modulating function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular chaperone function regulator
  • Molecular chaperone function regulator
  • Molecular chaperone function regulator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0223] Example 1 Relationship between induction of HSP70 and time when using A-431 cells derived from human epithelial carcinoma

[0224] (Methods) A-431 cells were cultured on a 12-well plate, and when the cell proliferation reached about 70%-80%, compound A and the control drug gefitinib were added to 10 μM, respectively.

[0225] DMSO (0.1%) was added to the control group. After addition, cells were harvested 6, 9, 12 and 24 hours later, and cell extracts were prepared. The expression of HSP70 protein in the cell extract was detected by using HSP70 specific antibody by Western blot method. T / C (%) was calculated by taking the amount of chemiluminescence of the HRP-labeled secondary antibody on the PVDF membrane as the expression level of HSP70, and taking the expression level of HSP70 in the cells in the control well as 100.

[0226] The result is shown in Figure 1.

[0227] (Results) In A-431 cells treated with compound A (-○-), the expression of HSP70 increased over ti...

Embodiment 2

[0229] Example 2 Induction of HSP70 in various human tumor-derived cells

[0230] (Method) Regarding induction of HSP70 by compound A, induction in various human tumor cells was examined.

[0231] TE-8 cells, NCI-H520 cells, HPAC cells, DU145 cells, KPL-4 cells, MKN-45 cells, HL-60 cells and DLD-1 cells were respectively cultured in 12-well plates.

[0232] When the cell proliferation reached about 70-80%, the compound A and the control drug gefitinib were added to 10 μM respectively. DMSO was added to the control group (0.1%). After the addition, the cells were collected 9 hours later, and a cell extract was prepared. The expression of HSP70 protein in each tumor cell extract was detected by Western blot method using HSP70 specific antibody.

[0233] The result is shown in Figure 2.

[0234] (Results) The expression of HSP70 was increased in any of the human tumor-derived cells treated with Compound A for 9 hours, compared to the DMSO-treated control group. In contrast, ...

Embodiment 3

[0236] Example 3 Inhibition of HSP90 Guest Protein Expression

[0237] (Methods) The effect of compound A on the expression of HSP90 chaperone guest proteins EGFR, HER2, ERα, AR, AKT and CDK4 was detected.

[0238] MCF-7 cells were cultured in a culture dish (10 cm in diameter), and when the cell proliferation reached about 70-80%, compound A and the control drug gefitinib were added to 10 μM respectively. Geldanamycin (1 μM) was added to the positive control group, and DMSO (0.1%) was added to the negative control group.

[0239] Cells were harvested 24 hours after addition of the compounds and divided into two. Cell extracts were prepared from half of the cells, and cytoplasmic and nuclear fractions were prepared from the remaining half of the cells. Cytoplasmic fractions and nuclear fractions were prepared using NER-PER (trademark) nuclear and cytoplasmic extractant (manufactured by PIERCE, #78833). Using specific antibodies to each object, the expression of the object i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A molecular chaperone function regulator which contains as an active ingredient a quinazoline derivative represented by the following general formula (I):(wherein the definitions of the symbols are the same as those in the claims), a pharmaceutically acceptable salt of the derivative, a hydrate or solvate of either, an optical isomer or racemate of any of these, or a diastereomer mixture of any of these.

Description

technical field [0001] The present invention relates to the prevention and / or treatment of diseases associated with heat shock proteins, wherein a compound that regulates the function of a molecular chaperone is used as an active ingredient. Background technique [0002] Heat shock proteins (hereinafter sometimes denoted as HSPs) are constitutively expressed in cells, and they perform chaperone functions such as folding and transporting newly translated and synthesized proteins to organelles. In addition, when cells are stimulated, HSP is induced to express and prevent protein denaturation, or promote the breakdown of denatured protein when the denaturation is severe. [0003] Examples of HSP are not limited, and examples include HSP70, HSP90 and the like. For example, HSP90 does not function independently as a chaperone, but cooperates with cochaperones such as HSP40 and HSP70. This function is regulated by a complex process in which various co-partners intervene and exch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/94A61K31/517A61P13/08A61P15/00A61P35/00A61P35/02A61P43/00
CPCC07D417/06C07D405/06C07D403/12C07D401/06C07D239/94C07D403/06A61K31/517A61P5/00A61P13/08A61P15/00A61P35/00A61P35/02A61P43/00C07D239/88
Inventor 铃木毅藤井明启中村秀男吉川勉
Owner MITSUBISHI TANABE PHARMA CORP